Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer
{{output}}
Background: Non-small cell lung cancer (NSCLC) treatment often involves a combination of first-line immunotherapy (IO) and chemotherapy, with platinum-based regimens as alternatives. Nivolumab monotherapy is a widely used second-... ...